The company was founded in 2016 and provides clinical expertise, commercialization know-how, and growth capital to help these companies create tomorrow's commercial blockbusters. They seek visionary entrepreneurs, proven teams, and strong IP to address large unmet needs in ophthalmology and are a focused venture capital fund from round A to commercialization, with target investments ranging from $500K to $5M in financing rounds ranging from $5M to $15MM. They aim to be lead investors and a partner of choice in their deals, bringing a strong KOL doctor partnership to the table. Their fund performance net of fees is a 30% IIR, placing them in the top decile of US venture funds.